U.S. Denies Approval of XenoPort, Inc., GlaxoSmithKline RLS Drug; Xenoport
Reuters -- U.S. regulators have denied approval for a drug from XenoPort (XNPT.O) and GlaxoSmithKline (GSK.L) to treat restless legs syndrome because of a potential link to cancer found in rats.